Human T-cell lymphotropic virus type 1 oncogenesis and cell-to-cell spread
DOI:
https://doi.org/10.47672/ejb.913Keywords:
Human T-cell lymphotropic virus type 1, Adult T-cell leukemia/lymphoma, HBZ, Tumorigenesis, innate immunity, Tax.Abstract
Exploring host-HTLV-1 interactions and the molecular processes underpinning HTLV-1-mediated carcinogenesis is crucial for establishing effective treatments for viral infection and associated leukemia/lymphoma. Several HTLV-1 proteins have been shown to play important roles in the cellular transformation and immortalization of infected T cells. Through interactions with MAVS, STING, and RIP1, the HTLV-1 oncoprotein Tax suppresses the innate IFN response, resulting in the inhibition of TBK1-mediated phosphorylation of IRF3/IRF7. The HTLV-1 protein HBZ affects genomic integrity and inhibits target cell death and autophagy. Furthermore, it has been discovered that HBZ promotes the growth of ATL cells and aids in the evasion of infected cells from immunosurveillance. It currently appears that the efficacy of an individual's cytotoxic T cell (CTL) response to HTLV-1 is the most important single predictor of that person's provirus load, which can differ by more than 10,000-fold amongst HTLV-1-infected persons. We examine recent improvements in our knowledge of the pathophysiology, or underlying processes, of the illness produced by HTLV-1 infection in this article. Furthermore, we explore the future approach for targeting HTLV-1-associated malignancies and anti-HTLV-1 therapies. The pathogenic agent of adult T-cell leukemia/lymphoma (ATL) is human T-cell lymphotropic virus type 1 (HTLV-1). ATL is a fast-developing clonal tumour of CD4+ T cells which are cellular and viral protein interactions and pave the way for the discovery of new classes of cellular modulators, which may induce Tax oncogenesis and its impact on survival signalling pathways such as the NF-B and PI3K-Akt pathways, therapeutic target opportunities for ATL have been presented in two collaborative studies.
Downloads
References
Romanelli MG, Diani E, Bergamo E, Casoli C, Ciminale V, Bex F, et al. Highlights on distinctive structural and functional properties of HTLV Tax proteins. Front Microbiol 2013; 4: 271.
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77: 7415–9.
Van DS, Salemi Mvandamme AM. Dating the origin of the African human T-cell lymphotropic virus type-I(HTLV-I) subtypes. Mol Biol Evol 2001; 18: 661–71.
Hajj HE, Nasr R, Kfoury Y, Dassouki Z, Nasser R, Kchour G, et al. Animal models on HTLV-1 and related viruses: what did we learn? Front Microbiol 2012; 3: 333.
Hinuma Y, Miyoshi I. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981; 78: 6476–80.
Gessain A, Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3: 388.
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3: 388.
Treviño A, García J, Mendoza CD, Benito R, Aguilera A, Ortíz DL, et al. Prevalence of HTLV-1/2 infections in Spain: a cross-sectional hospital-based survey. AIDS Res Hum Retroviruses 2010; 26: 861– 4.
Gessain A, Mahieux R. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, therapeutic aspects. Rev Neurol (Paris) 2012; 168: 257–69.
Yamagishi M, Watanabe T. Molecular hallmarks of adult T cell leukemia. Front Microbiol 2012; 3: 334.
Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 270–80.
Dan LL, Gelmann EP, Cossman J, Young RA, Gallo RC, O'brien SJ, et al. Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature 1984; 310: 505–6.
Koyanagi Y, Itoyama Y, Nakamura N, Takamatsu K, Kira JI, Iwamasa T, et al. In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology 1993; 196: 25–33.
Gakura, T., Stinchcombe, J. C., Goon, P. K., Taylor, G. P., Weber, J. N., Griffiths, G. M., Tanaka, Y., Osame, M. & Bangham, C. R. (2003). Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299, 1713–1716.
Goon, P. K. C., Hanon, E., Igakura, T., Tanaka, Y., Weber, J. N., Taylor, G. P. & Bangham, C. R. M. (2002). High frequencies of Th1 type CD4+ T-cells specific to HTLV-I Env and Tax proteins in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Blood 99, 3335–3341.
Kannagi, M., Sugamura, K., Kinoshita, K., Uchino, H. & Hinuma, Y. (1984). Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia/lymphoma patient. J Immunol 133, 1037–1041.
Townsend, A. R., Rothbard, J., Gotch, F. M., Bahadur, G., Wraith, D. & McMichael, A. J. (1986). The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44, 959–968.
Bangham, C. R. M. (2002). Genetics and dynamics of the immune response to HTLV-I. Gann Monogr Cancer Res 50, 397–402.
Bangham, C. R. M., Kermode, A. G., Hall, S. E. & Daenke, S. (1996). The cytotoxic T-lymphocyte response to HTLV-I: the main determinant of disease? Semin Virol 7, 41–48.
Pique C, Jones KS. Pathways of cell-cell transmission of HTLV-1. Front Microbiol 2012; 3: 378.
Carneiroproietti ABF, Amarantodamasio MS, Lealhoriguchi CF, Bastos RHC, Seabrafreitas G, Borowiak DR, et al. Mother-to-child transmission of human T-cell lymphotropic viruses-1/2: what we know, and what are the gaps in understanding and preventing this route of infection. J Pediatric Infect Dis Soc 2014; 3: S24–S29.
Percher F, Jeannin P, Martin-Latil S, Gessain A, Afonso PV, Vidy-Roche A, et al. Mother-to-child transmission of HTLV-1 epidemiological aspects, mechanisms and determinants of mother-to-child transmission. Viruses 2016; 8. pii: E40.
Kazanji M, Mouingaondémé A, Lekanadoukietenna S, Caron M, Makuwa M, Mahieux R, et al. Origin of HTLV-1 in hunters of nonhuman primates in central Africa. J Infect Dis 2015; 211: 361–5.
Tanaka T, Hirata T, Parrott G, Higashi Arakawa M, Kinjo T, Kinjo T, et al. Relationship among strongyloides stercoralis infection, human T-cell lymphotropic virus type 1 infection, and cancer: a 24-year Cohort Inpatients Study in Okinawa, Japan. Am J Trop Med Hyg 2016; 94: 365–70. 20 Chen JL, Limnander A, Rothman PB. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 2008; 111: 1677–85.
Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994; 305: 253–64.
Huebner RJ, Todaro GJ. Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci U S A 1969; 64: 1087– 94.
Vedham V, Verma M, Mahabir S. Early-life exposures to infectious agents and later cancer development. Cancer Med 2015; 4: 1908– 22.
Lehky TJ, Flerlage N, Mcfarland HF, Jacobson DS, Katz D, Houff S, et al. Human T-cell lymphotropic virus type II–associated myelopathy: Clinical and immunologic profiles. Ann Neurol 1996; 40: 714–23.
Eiraku N, Novoa P, da Costa Ferreira M, Monken C, Ishak R, da Costa Ferreira O, et al. Identification and characterization of a new and distinct molecular subtype of human T-cell lymphotropic virus type 2. J Virol 1996; 70: 1481–92.
Verdonck K, González E, Van DS, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7: 266–81.
Roucoux DF, Murphy EL. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev 2004; 6: 144–54.
Barbeau B, Mesnard JM. Making sense out of antisense transcription in human T-cell lymphotropic viruses (HTLVs). Viruses 2011; 3: 456– 68.
Younis I, Green PL. The human T-cell leukemia virus Rex protein. Front Biosci 2005; 10: 431–45.
Switzer WM, Qari SH, Wolfe ND, Burke DS, Folks TM, Heneine W. Ancient origin and molecular features of the novel human T-lymphotropic virus type 3 revealed by complete genome analysis. J Virol 2006; 80: 7427–38.
Feuer G, Green PL. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene 2005; 24: 5996–6004.
Switzer WM, Qari SH, Wolfe ND, Burke DS, Folks TM, Heneine W. Ancient origin and molecular features of the novel human T-lymphotropic virus type 3 revealed by complete genome analysis. J Virol 2006; 80: 7427–38.
Calattini S, Chevalier SA, Duprez R, Afonso P, Froment A, Gessain A, et al. Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein. J Virol 2006; 80: 9876–88.
Green PL, Chen IS. Regulation of human T cell leukemia virus expression. FASEB J 1990; 4: 169–75.
Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, et al. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med 2004; 10: 197–201.
Silic BM, Cavallari IN, Vidali S, Chieco BL, Di LF, Saggioro D, et al. Redox regulation of T-cell turnover by the p13 protein of human T-cell leukemia virus type 1: distinct effects in primary versus transformed cells. Blood 2010; 116: 54–62.
Andresen V, Pisemasison CA, Sinhadatta U, Bellon M, Valeri V, Washington PR, et al. Suppression of HTLV-1 replication by Taxmediated rerouting of the p13 viral protein to nuclear speckles. Blood 2011; 118: 1549–59.
Van PN, Gold H, Andresen V, Schwartz O, Jones K, Ruscetti F, et al. Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. Proc Natl Acad Sci U S A 2010; 107: 20738–43.
Proietti FA, Carneiroproietti ABF, Catalansoares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24: 6058–68.
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77: 7415–9.
Semmes OJ, Jeang KT. Localization of human T-cell leukemia virus type 1 tax to subnuclear compartments that overlap with interchromatin speckles. J Virol 1996; 70: 6347–57.
Nicot C, Feng T, Giam CZ. Cytoplasmic forms of human T-cell leukemia virus type 1 Tax induce NF-κB activation. J Virol 1998; 72: 6777–84.
Burton M, Upadhyaya CD, Maier B, Hope TJ, Semmes OJ. Human T-cell leukemia virus type 1 Tax shuttles between functionally discrete subcellular targets. J Virol 2000; 74: 2351–64.
Hua C, Cenciarelli C, Shao Z, Vidal M, Parks WP, Pagano M, et al. Human T cell leukemia virus type 1 Tax associates with a molecular chaperone complex containing hTid-1 and Hsp70. Curr Biol 2001; 11: 1771–5.
A l e fa n t i s T, B a r m a k , H a rh a j E W, G r a n t C , W i g d a h l B . Characterization of a nuclear export signal within the human T cell leukemia virus type I trans activator protein Tax. J Clin Oncol 2003; 278: 21814–22.
Yin MJ, Paulssen EJ, Seeler JS, Gaynor RB. Protein domains involved in both in vivo and in vitro interactions between human T-cell leukemia virus type I tax and CREB. J Virol 1995; 69: 3420–32.
Suzuki T, Fujisawa JI, Toita M, Yoshida M. The trans-activator tax of human T-cell leukemia virus type 1 (HTLV-1) interacts with cAMP responsive element (CRE) binding and CRE modulator proteins that bind to the 21-base-pair enhancer of HTLV-1. Proc Natl Acad Sci U S A 1993; 90: 610–4.
Goren I, Semmes OJ, Jeang KT, Moelling K. The amino terminus of Tax is required for interaction with the cyclic AMP response element binding protein. J Virol 1995; 69: 5806–11.
Chen L, Liu D, Zhang Y, Zhang H, Cheng H. The autophagy molecule Beclin 1 maintains persistent activity of NF-κB and Stat3 in HTLV-1- transformed T lymphocytes. Biochem Biophys Res Commun 2015; 465: 739–45.
Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008; 455: 674–8.
Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNAmediated, type I interferon-dependent innate immunity. Nature 2009; 461: 788–92.
Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005; 24: 5986–95.
Hollingworth R, Grand RJ. Modulation of DNA damage and repair pathways by human tumour viruses. Viruses 2015; 7: 2542–91.
Jeang KT, Giam CZ, Majone F, Aboud M. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004; 279: 31991–4.
Kao SY, Marriott SJ. Disruption of nucleotide excision repair by the human T-cell leukemia virus type 1 Tax protein. J Virol 1999; 73: 4299–304.
Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 1999; 73: 4786– 93.
Pisemasison CA, Mahieux R, Jiang H, Ashcroft M, Radanovich M, Duvall J, et al. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. Mol Cell Biol 2000; 20: 3377– 86.
Sun SC, Ballard DW. Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular I kappaB kinases. Oncogene 1999; 18: 6948–58.
Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290: 1717–21.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Tehreem Khalil, Samman, Zaynab Jawad, Zunaira Hakeem, Aemin Rasheed, Fareeha Sohail, Iqra Asad, Shehreen Sohail, Hamza Rana, Sana Saleem
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
